ArticleRheumatology advances in practice2025
The IgA Vasculitis Study: the evolution of a cross-sectional cohort into a trial-ready cohort.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical, laboratory, and pathological correlates of crescent formation in biopsy-proven pediatric IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this report is to describe a single-centre cohort study and its evolutionary stages into a trial-ready cohort with the vision of stopping kidney failure secondary to IgA vasculitis (IgAV). Methods: The IgA Vasculitis Study was established as a single-centre, cross-sectional cohort study recruiting children with a clinical diagnosis of IgAV and has evolved into a trial-ready framework. Sociodemographic and clinical data, as well as corresponding biosamples, were collected longitudinally and the natural history of the first 100 recruits is provided. Results: The IgA Vasculitis Study commenced in June 2019. The first 100 children recruited to the study had a mean age of 7.3 years (s.d. 3.7) and a male:female ratio of 1.5:1. At presentation, all children had a lower limb-predominant rash, 76% had musculoskeletal involvement, 43% gastrointestinal involvement and 23% met the definition of nephritis. Most children (54%) were discharged after 6 months, however, 17% required paediatric nephrology input. The mean timing of onset for nephritis was 25.5 days (s.d. 22.9) following disease presentation (range 0.0-101 days). Fourteen children with IgAV nephritis (IgAV-N) received immunosuppression. Children with an older age, residing in more affluent areas, with gastrointestinal involvement or a positive urine dipstick (for proteinuria and/or haematuria) at presentation had greater odds of developing nephritis. Children with IgAV-N had statistically significantly more hospital visits and unplanned hospital admissions ( Conclusion: Nephritis remains a serious consequence of IgAV with little evidence to guide management. This report outlines an exemplar study to advance the field towards better interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.